Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160

NCT01780545 is registered in ClinicalTrials.gov with Noah Hahn, M.D. as lead sponsor.

NCT NCT01780545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01780545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160
Lead sponsor
Noah Hahn, M.D.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2013
Completion date
October 31, 2017
Enrollment
200 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, urothelial carcinoma